Serological proteomic profiling uncovered CDK5RAP2 as a novel marker in benign prostatic hyperplasia

Area of Science:

• Urology
• Proteomics
• Biomarker Discovery

Background:

• Benign prostatic hyperplasia (BPH) affects over 50% of men over 50.
• Current diagnostic methods like prostate-specific antigen (PSA) have limitations in distinguishing BPH from prostate cancer (PCa).
• There is a need for improved serum markers for accurate BPH diagnosis and intervention.

Purpose of the Study:

• To identify novel serum proteomic alterations in BPH patients.
• To discover reliable biomarkers for differentiating BPH from PCa.
• To enhance early detection and clinical management of BPH.

Main Methods:

• Proteomic analysis using data-independent acquisition mass spectrometry on serum samples from healthy individuals, BPH patients, and PCa patients.
• Bioinformatic evaluation for proteomic profiling and candidate marker selection.
• Validation of a candidate marker using ELISA assay.

Main Results:

• Free PSA levels correlated with prostate volume in BPH patients.
• Distinct proteomic profiles were observed between BPH and PCa serum samples.
• CDK5RAP2 was identified as a significant biomarker for distinguishing BPH from PCa with high accuracy (AUC=0.900).

Conclusions:

• The study identified novel serum markers, including CDK5RAP2, for BPH.
• These findings contribute to a better understanding of BPH serum characteristics.
• The identified markers may aid in the early diagnosis and intervention of BPH.